Investor Watch | FDA Approves atai PCN-101 R-ketamine Program for Treatment-Resistant Depression

An enantiomer of Ketamine (R-Ketamine) has been approved by the United States Food and Drug Administration (FDA) for clinical trials in order to combat conditions like depression, treatment-resistant depression (TRD) in particular.
Ketamine, a dissociative anesthetic developed in the 60’s, is primarily used for veterinary and human anesthesia. Sometimes its prescribed off-label, of course under medical supervision in a clinical setting, but if these trials underway provide convincing results, then R-ketamine could be a safe anti-depressant for people to use in their own homes.